Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid CAS 486460-00-8 Tsabtace ≥99.5% (HPLC) Sitagliptin Phosphate Monohydrate Intermediate
Samar da Sitagliptin Phosphate Monohydrate Matsakaici masu alaƙa:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Matsakaici CAS 486460-21-3
| Sunan Sinadari | Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid |
| Makamantu | (R) - Sitagliptin N-Boc-Acid rashin tsabta |
| Lambar CAS | 486460-00-8 |
| Lambar CAT | Saukewa: RF-PI1192 |
| Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
| Tsarin kwayoyin halitta | Saukewa: C15H18F3NO4 |
| Nauyin Kwayoyin Halitta | 333.31 |
| Matsayin narkewa | 136.0 ~ 138.0 ℃ |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Fari zuwa Kashe-Farin Foda |
| Gano ta HPLC | Lokacin Riƙewar Samfurin Yana Daidaita Tare da Matsayin Magana |
| Asara akan bushewa | ≤0.50% |
| Sulfated Ash | ≤0.50% |
| Karfe masu nauyi | <20ppm |
| Isomer | ≤0.50% |
| Abubuwa masu alaƙa | |
| Najasa A | ≤0.50% |
| Duk Wani Rashin Tsabta Guda Daya | ≤0.50% |
| Jimlar ƙazanta | ≤0.50% |
| Tsafta | ≥99.5% (HPLC) |
| Matsayin Gwaji | Matsayin Kasuwanci |
| Amfani | Matsakaicin Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9) |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.
Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid (CAS: 486460-00-8) shine muhimmin tsaka-tsaki don shirye-shiryen sitagliptin.Sitagliptinphosphate shine farkon dipeptidase -IV(DPP-4) mai hanawa wanda FDA ta amince dashi a cikin 2006. Ana amfani dashi don maganin nau'in ciwon sukari na II.Yana da tasirin hypoglycemic a bayyane lokacin amfani da shi kadai ko a hade tare da metformin da pioglitazone, kuma ba shi da haɗari don ɗauka, da jurewa, tare da ƴan halayen mara kyau.A watan Agustan 2009, Ƙungiyar Tarayyar Turai ta amince da maganin a matsayin magani na farko don maganin ciwon sukari na 2.Bayan 2011, ɗaya bayan ɗaya ƙasashe sun amince da haɗin sitagliptin phosphate da alpha glycosidase inhibitors ko insulin.Sitagliptin phosphate shine farkon wanda FDA ta amince da dipeptidyl peptidase-IV inhibitor da za a yi amfani da shi wajen kula da nau'in ciwon sukari na 2 da nisa, ƙarƙashin sunan kasuwanci Januvia.
